Core Viewpoint - Scilex Holding Company has successfully closed the exercise of existing warrants, generating approximately $20.3 million in gross proceeds, which will be used for working capital and general corporate purposes [1][4]. Group 1: Warrants and Proceeds - The company exercised two sets of existing warrants, totaling 904,396 shares, at a reduced exercise price of $22.51 per share [1]. - The April 2024 Warrants were originally priced at $38.50 per share, while the December 2024 Warrants had an exercise price of $22.72 per share [1]. - The gross proceeds from the exercise of these warrants were approximately $20.3 million before deducting fees and expenses [1]. Group 2: New Warrant Issuance - In exchange for the immediate cash exercise of the existing warrants, the company issued a new unregistered warrant for 1,356,594 shares at an exercise price of $29.00 per share, which is exercisable immediately and has a five-year term [3]. - The new warrant was offered in a private placement under Section 4(a)(2) of the Securities Act and Regulation D [5]. Group 3: Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [8]. - The company's commercial products include ZTlido, ELYXYB, and Gloperba, which target significant unmet medical needs [9][10]. - Scilex has three product candidates in development, including SP-102, SP-103, and SP-104, which are aimed at various pain management indications [10].

PALO ALTO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of (i) 428,572 shares of common ...

PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that, with respect to the voluntary distribution by Datavault AI Inc. (“Datavault AI”) (Nasdaq: DVLT) of Dream Bowl 2026 Meme Coins to record holders o ...

Core Viewpoint - Scilex Holding Company has repurchased 3,130,000 warrants from Oramed Pharmaceuticals for $13 million, as part of a larger option agreement to repurchase a total of 6,500,000 warrants for $27 million, with the option to repurchase the remaining warrants by December 31, 2025 [1] Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [3][4] - The company aims to address high unmet needs in the market with non-opioid therapies, enhancing patient outcomes [3] Commercial Products - Scilex's commercial products include: - ZTlido (lidocaine topical system) 1.8%, approved for neuropathic pain relief associated with postherpetic neuralgia [3] - ELYXYB, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [3] - Gloperba, the first liquid oral version of colchicine for gout flare prophylaxis [3] Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA), a viscous gel formulation for epidural injections to treat lumbosacral radicular pain, which has completed a Phase 3 study and received Fast Track status from the FDA [4] - SP-103, a next-generation lidocaine topical system for acute pain, which has completed a Phase 2 trial and also received Fast Track status [4] - SP-104, a low-dose naltrexone hydrochloride capsule for fibromyalgia treatment [4]

Core Insights - Scilex Holding Company has entered into a Securities Purchase Agreement to exchange $200 million of common stock of its subsidiary Semnur Pharmaceuticals for $200 million in Bitcoin [1][2] Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [1][7] - The company aims to address high unmet needs in the market with non-opioid therapies [7] Transaction Details - The institutional investor will purchase 12,500,000 shares of Semnur common stock at $16.00 per share, subject to adjustments for various corporate actions [2] - The transaction is expected to close around September 23, 2025, pending customary closing conditions [2] Regulatory Information - The shares sold under the SPA are not registered under the Securities Act and cannot be resold in the U.S. without proper registration or exemption [3] Strategic Partnerships - Scilex has engaged Biconomy.com to assist in developing cryptocurrency strategies, including reserve buildup and treasury management [5] Product Portfolio - Scilex's commercial products include ZTlido, ELYXYB, and Gloperba, targeting various pain management needs [7][8] - The company has three product candidates in development: SP-102, SP-103, and SP-104, focusing on non-opioid pain therapies [9][11]

Core Viewpoint - Semnur Pharmaceuticals, Inc. has received approval from Denali Capital Acquisition Corp's shareholders for a business combination, which is expected to close in September 2025, allowing Semnur to operate as the combined entity [1][2]. Company Overview - Semnur Pharmaceuticals is a majority-owned subsidiary of Scilex Holding Company, focusing on non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [1][4]. - Scilex Holding Company is dedicated to developing and commercializing therapies that address high unmet medical needs in pain management [4]. Business Combination Details - The business combination was approved during an Extraordinary General Meeting held on September 3, 2025, where all proposals were accepted [2]. - Denali has filed a Current Report on Form 8-K with the SEC to disclose the voting results from the meeting [3]. Product Portfolio - Scilex's commercial products include: - ZTlido, a topical lidocaine product for neuropathic pain [4]. - ELYXYB, an FDA-approved oral solution for acute migraine treatment [4]. - Gloperba, a liquid oral version of colchicine for gout flare prophylaxis [4]. - Scilex has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel for treating lumbosacral radicular pain, which has completed a Phase 3 study [5]. - SP-103, a next-generation lidocaine topical system for acute pain, recently completing a Phase 2 trial [5]. - SP-104, a low-dose naltrexone for fibromyalgia treatment [5]. Market Position - Semnur is positioned as a late-stage specialty pharmaceutical company focused on novel non-opioid pain therapies, with its lead product candidate being SP-102 [8].

Core Viewpoint - Scilex Holding Company is advancing a business combination with Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, focusing on non-opioid pain management products, with the SEC declaring the registration statement effective [1][6]. Company Overview - Scilex is dedicated to acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [5]. - The company’s commercial products include ZTlido, ELYXYB, and Gloperba, targeting high unmet medical needs [5]. Business Combination Details - An extraordinary general meeting for Denali shareholders is scheduled for September 3, 2025, to approve the proposed business combination [2][6]. - The combined company will be renamed Semnur Pharmaceuticals, Inc. upon closing the business combination [6]. Product Pipeline - Scilex has three product candidates: SP-102 (SEMDEXA), SP-103, and SP-104, targeting various pain management needs and conditions [7]. - SP-102 is a novel gel formulation for epidural injections, while SP-103 is a next-generation lidocaine topical system [7]. Market Position - Scilex aims to address significant market opportunities in non-opioid therapies for pain management, focusing on improving patient outcomes [5].

Core Insights - Scilex Holding Company announced a publication regarding GLOPERBA dosing adjustments in a peer-reviewed journal, emphasizing its focus on non-opioid pain management products for various conditions [1][5] Company Overview - Scilex Holding Company is dedicated to acquiring, developing, and commercializing non-opioid pain management products aimed at treating acute and chronic pain, neurodegenerative diseases, and cardiometabolic diseases [1][6] - The company’s commercial products include ZTlido, ELYXYB, and GLOPERBA, with GLOPERBA being the first and only liquid oral version of colchicine for gout flare prophylaxis [6][9] Product Details - GLOPERBA allows for precision dosing and is particularly beneficial for over 70% of gout patients who have comorbid conditions requiring dose adjustments [2][4] - The publication highlights the importance of precise dosing for patients with renal impairment, suggesting specific dosages of 0.48 mg for moderate and 0.3 mg for severe renal impairment to maintain therapeutic levels and enhance safety [4][5] Clinical Significance - The publication is expected to provide essential data to guide clinical dosing of colchicine in patients suffering from gout and chronic renal failure, addressing a significant clinical need [5]

Core Insights - Scilex Holding Company has received FDA approval for Orphan drug designation for colchicine to treat pericarditis, enhancing its portfolio in non-opioid pain management products [1][3]. Company Overview - Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, with a commitment to improving patient outcomes [5][10]. - The company is headquartered in Palo Alto, California [9][11]. Product Portfolio - Scilex's commercial products include: - ZTlido (lidocaine topical system) 1.8% for neuropathic pain relief [5][7]. - ELYXYB, an oral solution for acute migraine treatment [5][7]. - Gloperba, the first liquid oral version of colchicine for gout flare prophylaxis [6][7]. - The company has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel for epidural injections targeting lumbosacral radicular pain, which has completed Phase 3 studies [8]. - SP-103, a next-generation lidocaine topical system for acute pain, recently completing Phase 2 trials [8]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia treatment [8]. Regulatory Insights - The Orphan Drug Act allows the FDA to grant orphan designation to drugs intended for rare diseases, which can lead to seven years of market exclusivity upon first approval [3].

Core Insights - Oramed Pharmaceuticals Inc. is advancing its proprietary oral drug delivery technology through a joint venture named OraTech Pharmaceuticals, Inc. with Hefei Tianhui Biotech Co., Ltd. [4][5] - The joint venture aims to initiate a Phase 3 clinical trial in the U.S. for oral insulin, focusing on key patient subpopulations to demonstrate efficacy [6][11] - HTIT has submitted a Marketing Authorization Application for the oral insulin capsule in China, with commercialization preparations underway [7][11] - Oramed plans to distribute OraTech stock to its shareholders via a dividend, coinciding with OraTech's public trading debut on Nasdaq [8][11] - A cash dividend of approximately $0.25 per share is being evaluated to offset potential tax liabilities related to the OraTech stock distribution [9][11] - Oramed's investment in Scilex Holding Company has generated $70 million from a secured loan agreement, with additional payments expected [12][13] - The company maintains a strong financial position, supported by strategic transactions and disciplined capital allocation [13] - Future growth strategies include pursuing acquisitions and partnerships to leverage technology development [14] Joint Venture and Product Development - The OraTech joint venture combines Oramed's drug delivery technology with HTIT's manufacturing capabilities, aiming to set new standards for oral protein delivery [5][6] - OraTech is expected to receive royalties from sales in China, enhancing its revenue potential [7][11] Financial Strategies - Oramed is working on achieving Nasdaq trading status for OraTech and plans to distribute the majority of its ownership in OraTech to shareholders [8][11] - The company is also exploring cash dividends to enhance shareholder value and mitigate tax concerns [9][11] Strategic Investments - Oramed's investment in Scilex includes a royalty stream from multiple products, with expected royalties of $400,000 for Q4 2024 [12][16] - The company holds a 2% royalty on worldwide sales for ELYXYB and GLOPERBA, with additional profit-sharing arrangements [16]